These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 31135957)

  • 21. The clinical significance of HOXA9 promoter hypermethylation in head and neck squamous cell carcinoma.
    Zhou C; Li J; Li Q; Liu H; Ye D; Wu Z; Shen Z; Deng H
    J Clin Lab Anal; 2019 Jun; 33(5):e22873. PubMed ID: 30843252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients.
    Kostareli E; Hielscher T; Zucknick M; Baboci L; Wichmann G; Holzinger D; Mücke O; Pawlita M; Del Mistro A; Boscolo-Rizzo P; Da Mosto MC; Tirelli G; Plinkert P; Dietz A; Plass C; Weichenhan D; Hess J
    Epigenetics; 2016; 11(1):61-73. PubMed ID: 26786582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA methylation association with stage progression of head and neck squamous cell carcinoma.
    Ghafarpour V; Khansari M; Banaei-Moghaddam AM; Najafi A; Masoudi-Nejad A
    Comput Biol Med; 2021 Jul; 134():104473. PubMed ID: 34034219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel approaches to global mining of aberrantly methylated promoter sites in squamous head and neck cancer.
    Worsham MJ; Chen KM; Stephen JK; Havard S; Benninger MS
    Otolaryngol Head Neck Surg; 2010 Jul; 143(1):116-21, 121.e1-19. PubMed ID: 20620629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.
    Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H
    Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MAGEB2 is activated by promoter demethylation in head and neck squamous cell carcinoma.
    Pattani KM; Soudry E; Glazer CA; Ochs MF; Wang H; Schussel J; Sun W; Hennessey P; Mydlarz W; Loyo M; Demokan S; Smith IM; Califano JA
    PLoS One; 2012; 7(9):e45534. PubMed ID: 23029077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promoter Hypermethylation Profiling Identifies Subtypes of Head and Neck Cancer with Distinct Viral, Environmental, Genetic and Survival Characteristics.
    Choudhury JH; Ghosh SK
    PLoS One; 2015; 10(6):e0129808. PubMed ID: 26098903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic potential of KLOTHO and SFRP1 promoter methylation in head and neck squamous cell carcinoma.
    Alsofyani AA; Alsiary RA; Samkari A; Alhaj-Hussain BT; Khan JA; Al-Maghrabi J; Elaimi A; Al-Qahtani MH; Abuzenadah AM; Dallol A
    J Appl Genet; 2017 Nov; 58(4):459-465. PubMed ID: 28812223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and epigenetic somatic alterations in head and neck squamous cell carcinomas are globally coordinated but not locally targeted.
    Poage GM; Christensen BC; Houseman EA; McClean MD; Wiencke JK; Posner MR; Clark JR; Nelson HH; Marsit CJ; Kelsey KT
    PLoS One; 2010 Mar; 5(3):e9651. PubMed ID: 20300172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Head and neck squamous cell carcinoma: mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene.
    Tawfik HM; El-Maqsoud NM; Hak BH; El-Sherbiny YM
    Am J Otolaryngol; 2011; 32(6):528-36. PubMed ID: 21353335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter.
    Poli E; Zhang J; Nwachukwu C; Zheng Y; Adedokun B; Olopade OI; Han YJ
    PLoS One; 2015; 10(11):e0142224. PubMed ID: 26539832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer.
    Feng B; Shen Y; Pastor Hostench X; Bieg M; Plath M; Ishaque N; Eils R; Freier K; Weichert W; Zaoui K; Hess J
    Clin Cancer Res; 2020 Jul; 26(14):3616-3628. PubMed ID: 32161122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
    Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
    PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of epigenetic inactivation of vascular endothelial growth factor receptors in head and neck squamous cell carcinoma.
    Misawa Y; Misawa K; Kawasaki H; Imai A; Mochizuki D; Ishikawa R; Endo S; Mima M; Kanazawa T; Iwashita T; Mineta H
    Tumour Biol; 2017 Jul; 39(7):1010428317711657. PubMed ID: 28718364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylated genomic loci encoding microRNA as a biomarker panel in tissue and saliva for head and neck squamous cell carcinoma.
    Cao Y; Green K; Quattlebaum S; Milam B; Lu L; Gao D; He H; Li N; Gao L; Hall F; Whinery M; Handley E; Ma Y; Xu T; Jin F; Xiao J; Wei M; Smith D; Bornstein S; Gross N; Pyeon D; Song J; Lu SL
    Clin Epigenetics; 2018; 10():43. PubMed ID: 29636832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA promoter hypermethylation contributes to down-regulation of galactocerebrosidase gene in lung and head and neck cancers.
    Peng J; Chen B; Shen Z; Deng H; Liu D; Xie X; Gan X; Xu X; Huang Z; Chen J
    Int J Clin Exp Pathol; 2015; 8(9):11042-50. PubMed ID: 26617822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of methylation-driven genes for predicting the prognosis of patients with head and neck squamous cell carcinoma.
    Pan Y; Song Y; Cheng L; Xu H; Liu J
    J Cell Biochem; 2019 Dec; 120(12):19482-19495. PubMed ID: 31264288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unraveling most abundant mutational signatures in head and neck cancer.
    Plath M; Gass J; Hlevnjak M; Li Q; Feng B; Hostench XP; Bieg M; Schroeder L; Holzinger D; Zapatka M; Freier K; Weichert W; Hess J; Zaoui K
    Int J Cancer; 2021 Jan; 148(1):115-127. PubMed ID: 32930393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent epigenetic silencing of the PTPRD tumor suppressor in laryngeal squamous cell carcinoma.
    Szaumkessel M; Wojciechowska S; Janiszewska J; Zemke N; Byzia E; Kiwerska K; Kostrzewska-Poczekaj M; Ustaszewski A; Jarmuz-Szymczak M; Grenman R; Wierzbicka M; Bartochowska A; Szyfter K; Giefing M
    Tumour Biol; 2017 Mar; 39(3):1010428317691427. PubMed ID: 28345455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
    Shames DS; Girard L; Gao B; Sato M; Lewis CM; Shivapurkar N; Jiang A; Perou CM; Kim YH; Pollack JR; Fong KM; Lam CL; Wong M; Shyr Y; Nanda R; Olopade OI; Gerald W; Euhus DM; Shay JW; Gazdar AF; Minna JD
    PLoS Med; 2006 Dec; 3(12):e486. PubMed ID: 17194187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.